FDA News: FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

27Nov - by Editor - 0 - In STL.News



New drug Vitrakvi targets specific receptor kinase that promotes tumors

SILVER SPRING, MD – The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

This is the second time the agency has approved a cancer treatment based on a common biomarker across different types of tumors rather than the location in the body where the tumor originated. 

Continue reading FDA News: FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor at STL.News.



Source link